Menu Search
Equities

Boston Scientific Corp

BSX:NYQ

Boston Scientific Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)84.17
  • Today's Change1.60 / 1.94%
  • Shares traded3.77m
  • 1 Year change+58.72%
  • Beta0.7965
Data delayed at least 15 minutes, as of Sep 19 2024 16:56 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy12
Outperform19
Hold3
Sell0
Strong Sell0

Share price forecast in USD

The 30 analysts offering 12 month price targets for Boston Scientific Corporation have a median target of 87.50, with a high estimate of 100.00 and a low estimate of 78.00. The median estimate represents a 5.97% increase from the last price of 82.57.
High21.1%100.00
Med6.0%87.50
Low-5.5%78.00

Earnings history & estimates in USD

On Jul 24, 2024, Boston Scientific Corporation reported 2nd quarter 2024 earnings of 0.62 per share. This result exceeded the 0.58 consensus of the 27 analysts covering the company and exceeded last year's 2nd quarter results by 16.98%.
The next earnings announcement is expected on Oct 24, 2024.
Average growth rate+4.22%
Boston Scientific Corporation reported annual 2023 earnings of 2.05 per share on Jan 31, 2024.
Average growth rate+13.76%
More ▼

Revenue history & estimates in USD

Boston Scientific Corporation had 2nd quarter 2024 revenues of 4.12bn. This bettered the 4.02bn consensus of the 23 analysts covering the company. This was 21.57% above the prior year's 2nd quarter results.
Average growth rate+3.49%
Boston Scientific Corporation had revenues for the full year 2023 of 14.24bn. This was 12.29% above the prior year's results.
Average growth rate+7.81%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.